7 6 GA bispecific antibody: Combining validated complement regulation with VEGF or IL-6 inhibition as a therapeutic target for GA Administered via intravitreal injection Anti-IL-6 Fab Complement Receptor 1 Complement Receptor 1 Inhibits C3 convertase formation, simultaneously blocking all complement pathways at low concentrations Anti-VEGF Fab Prevents wet-AMD conversion Reduces inflammation -driven GA progression IL-6 + Complement VEGF + Complement
Interactive Corporate Presentation June 2026 Page 74 Page 76